Inventiva Management

Management criteria checks 2/4

Inventiva's CEO is Frederic Cren, appointed in Jan 2011, has a tenure of 13.83 years. total yearly compensation is €1.00M, comprised of 30.4% salary and 69.6% bonuses, including company stock and options. directly owns 6.45% of the company’s shares, worth €13.81M. The average tenure of the management team and the board of directors is 8.2 years and 7.8 years respectively.

Key information

Frederic Cren

Chief executive officer

€1.0m

Total compensation

CEO salary percentage	30.4%
CEO tenure	13.8yrs
CEO ownership	6.4%
Management average tenure	8.2yrs
Board average tenure	7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Frederic Cren's remuneration changed compared to Inventiva's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

Compensation vs Market: Frederic's total compensation ($USD1.06M) is above average for companies of similar size in the German market ($USD787.21K).

Compensation vs Earnings: Frederic's compensation has increased whilst the company is unprofitable.

CEO

Frederic Cren (58 yo)

13.8yrs

Tenure

€1,003,699

Compensation

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Frederic Cren	Co-Founder	13.8yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	4.46% € 9.6m
Jean Volatier	Deputy GM & CFO	12.3yrs	no data	0.17% € 368.5k
Alice Roudot-Ketelers	Chief Operating Officer	1.8yrs	no data	0.017% € 36.9k
Eric Duranson	General Counsel	3.3yrs	no data	0.017% € 36.9k
Nathalie Harroy	Head of Human Resources	12.8yrs	no data	0.075% € 161.6k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	no data	no data
Michael Cooreman	Chief Medical Officer	4.1yrs	no data	0.017% € 36.9k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	1.1yrs	no data	0.0086% € 18.4k

8.2yrs

Average Tenure

57.5yo

Average Age

Experienced Management: 6IV's management team is seasoned and experienced (8.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Frederic Cren	Co-Founder	8.5yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	8.5yrs	€938.43k	4.46% € 9.6m
Chris Buyse	Independent Director	7.8yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.8yrs	€61.20k	0.0035% € 7.6k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	no data
Xiaoqin Lu	Independent Director	6.5yrs	€43.20k	no data
Heinz Maeusli	Independent Director	5.5yrs	€49.20k	no data
Sven Francque	Member of Scientific Advisory Board	no data	no data	no data
Manal Abdelmalek	Member of Scientific Advisory Board	no data	no data	no data
Kenneth Cusi	Member of Scientific Advisory Board	no data	no data	no data
Glen Clack	Member of Scientific Advisory Board	no data	no data	no data
Gérard Zalcman	Scientific Advisory Board Member	no data	no data	no data

7.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 6IV's board of directors are considered experienced (7.8 years average tenure).

Inventiva Management

Management criteria checks 2/4

Key information

Recent management updates

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Insufficient new directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Full year 2023 earnings released: €2.44 loss per share (vs €1.31 loss in FY 2022)

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

First half 2023 earnings released: €1.32 loss per share (vs €0.72 loss in 1H 2022)

New major risk - Negative shareholders equity

New major risk - Financial position

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Full year 2022 earnings released: €1.31 loss per share (vs €1.27 loss in FY 2021)

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

First half 2022 earnings released: €0.72 loss per share (vs €0.60 loss in 1H 2021)

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

First quarter 2021 earnings released: €0.23 loss per share (vs €0.23 loss in 1Q 2020)

Full year 2020 earnings released: €0.99 loss per share (vs €1.29 loss in FY 2019)

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

New 90-day high: €12.92

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

New 90-day high: €11.34

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age